The Shake Up At Endo Pharma
Endo Pharma CEO Dave Holveck is diversifying the company from its core pain franchise into seemingly unrelated fields. Critics argue that he's neglecting its core strengths and acquiring mediocre assets, but he says such moves are necessary to address marketplace shifts.
You may also be interested in...
Endo CEO Reveals Glimpse Of New Strategy: Highlights Generics Potential
During Endo’s first quarter sales and earnings call, new CEO Rajiv De Silva said his strategic review of the specialty pharma is still underway but offered investors some initial thoughts on his plans for the company.
Endo’s Next Chapter Will Be Led By CEO De Silva
Former Valeant President De Silva joins Endo in the midst of a challenging year for the company, as two top-selling drugs face generic competition. De Silva will need to reenergize Endo and do so quickly if he is to maintain the early favor he appears to have won from investors.
Ikaria’s Hybrid Business Model Taps Big Pharma Trends
Although Ikaria focuses on a highly specialized segment of the hospital market, its integrated business model offers insights into continuum of care strategies that pharma companies are evaluating in a reimbursement-focused world. The company’s promising strategy could get a boost from key trial read-outs as soon as late 2012.